These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7876397)

  • 1. Pharmacokinetics of cefodizime in volunteers with normal or impaired renal function.
    Conte JE
    J Clin Pharmacol; 1994 Nov; 34(11):1066-70. PubMed ID: 7876397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of cefodizime in elderly patients with moderate or severe renal impairment.
    Veyssier P; Devillers A; Domart Y; Fourtillan JB; Bryskier A; Procyk T
    J Antimicrob Chemother; 1990 Nov; 26 Suppl C():77-81. PubMed ID: 2074255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of cefodizime in patients with various degrees of renal failure.
    Loffreda A; Lampa E; Lucarelli C; Amorena M; Contaldi C; Calderaro V; Rossi F
    Chemotherapy; 1999; 45(1):1-7. PubMed ID: 9876203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose linearity and other pharmacokinetics of cefodizime after single-dose intravenous administration.
    Dagrosa EE; Hajdú P; Malerczyk V; de Looze S; Seeger K; Grötsch H
    Clin Ther; 1987; 10(1):18-31. PubMed ID: 3450392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of cefodizime in normal individuals and in patients with renal failure.
    el Guinaidy MA; Nawishy S; Abd el Bary M; Sabbour MS
    Chemotherapy; 1991; 37(2):77-85. PubMed ID: 2032473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and dosage adjustment of cefotiam in renal impaired patients.
    Rouan MC; Binswanger U; Bammatter F; Theobald W; Schoeller JP; Guibert J
    J Antimicrob Chemother; 1984 Jun; 13(6):611-8. PubMed ID: 6088464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of cefmenoxime in patients with impaired renal function and in those undergoing hemodialysis.
    Konishi K
    Antimicrob Agents Chemother; 1986 Dec; 30(6):901-5. PubMed ID: 3468882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of cefotiam in patients with impaired renal function and in those undergoing hemodialysis.
    Konishi K; Ozawa Y
    Antimicrob Agents Chemother; 1984 Nov; 26(5):647-51. PubMed ID: 6097172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment.
    Patel IH; Sugihara JG; Weinfeld RE; Wong EG; Siemsen AW; Berman SJ
    Antimicrob Agents Chemother; 1984 Apr; 25(4):438-42. PubMed ID: 6329080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of cefodizime during continuous ambulatory peritoneal dialysis.
    Mendes P; Lameire N; Rosenkranz B; Malerczyk V; Damm D
    J Antimicrob Chemother; 1990 Nov; 26 Suppl C():89-93. PubMed ID: 2074257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefmenoxime pharmacokinetics in patients with renal insufficiency.
    Polk RE; Sica DA; Kerkering TM; Kline BJ; Patterson PM; Baggett JW
    Antimicrob Agents Chemother; 1984 Sep; 26(3):322-7. PubMed ID: 6095752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of cefodizime: a review of the data on file.
    Barré J
    J Antimicrob Chemother; 1990 Nov; 26 Suppl C():95-101. PubMed ID: 2074258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of cefodizime administered intravenously as a single-dose (1.0 and 2.0 g) to healthy adult volunteers.
    Bryskier A; Procyk T; Tremblay D; Lenfant B; Fourtillan JB
    J Antimicrob Chemother; 1990 Nov; 26 Suppl C():65-70. PubMed ID: 2074253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefmenoxime pharmacokinetics in healthy volunteers and subjects with renal insufficiency and on hemodialysis.
    Gambertoglio JG; Alexander DP; Barriere SL
    Antimicrob Agents Chemother; 1984 Dec; 26(6):845-9. PubMed ID: 6098220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.
    Blum RA; Kohli RK; Harrison NJ; Schentag JJ
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1470-6. PubMed ID: 2817847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
    Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
    Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of cefodizime following single doses of 0.5, 1.0, 2.0, and 3.0 grams administered intravenously to healthy volunteers.
    Lenfant B; Namour F; Logeais C; Coussediere D; Rivault O; Bryskier A; Surjus A
    Antimicrob Agents Chemother; 1995 Sep; 39(9):2037-41. PubMed ID: 8540712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of cefotaxime and its active metabolite in children with renal dysfunction.
    Paap CM; Nahata MC; Mentser MA; Mahan JD; Puri SK; Hubbard JW
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1879-83. PubMed ID: 1952862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of cefpiramide in volunteers with normal or impaired renal function.
    Conte JE
    Antimicrob Agents Chemother; 1987 Oct; 31(10):1585-8. PubMed ID: 3435107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function.
    Nilsen OG; Saltvedt E; Walstad RA; Marstein S
    Am J Med; 1992 Apr; 92(4A):38S-40S. PubMed ID: 1316068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.